Aralez Pharmaceuticals Inc. (ARLZ) Stock Rating Reaffirmed by Chardan Capital
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a report released on Wednesday. They currently have a $10.00 target price on the stock. Chardan Capital’s price objective would suggest a potential upside of 102.02% from the company’s previous close.
Separately, Guggenheim reiterated a “buy” rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a research note on Thursday, September 15th.
Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 3.32% during trading on Wednesday, hitting $4.95. The stock had a trading volume of 457,471 shares. The stock’s market capitalization is $322.94 million. The stock’s 50 day moving average is $5.29 and its 200 day moving average is $4.20. Aralez Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The company earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. The company’s quarterly revenue was up 142.3% on a year-over-year basis. On average, equities research analysts expect that Aralez Pharmaceuticals will post ($1.06) earnings per share for the current fiscal year.
In other news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total value of $873,000.00. Following the transaction, the director now directly owns 669,094 shares of the company’s stock, valued at approximately $3,894,127.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.77% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $100,000. Advisor Group Inc. acquired a new position in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $118,000. Knott David M acquired a new position in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $124,000. Alpine Partners VI LLC acquired a new position in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $133,000. Finally, LMR Partners LLP acquired a new position in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $145,000. 49.63% of the stock is currently owned by institutional investors and hedge funds.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Stock Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.